Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
Introduction
As the clinical and pathological responses of breast cancer to neoadjuvant chemotherapy are short-term markers for a long-term outcome 1, 2, it is important to identify accurately biological factors that may predict the response to neoadjuvant therapy. These factors should identify patients who will benefit most from treatment, and spare patients from the toxicity of treatment that is known to be ineffective. These factors could also provide mechanistics insights into understanding tumour biology. Recent retrospective studies have suggested a correlation between HER2 overexpression and a benefit from anthracycline therapy 3, 4, but a biological mechanism linking HER2 overexpression to anthracycline sensitivity is lacking. Topoisomerase II alpha (TopoIIα) is localised close to HER2 on chromosome 17 q12-q21 and the enzyme is a molecular target for anthracyclines [5]. Because of the physical proximity to HER2, TopoIIα is frequently co-amplified with HER2 in breast cancer [6]. This co-amplification could provide a plausible explanation for the link between HER2 overexpression and anthracycline response.
In the present study, the role of tumour grade, hormonal receptors (HR), Ki-67, HER-2 and TopoIIα status as predictive markers of response to neoadjuvant anthracycline-based chemotherapy was evaluated in primary tumour specimens from 119 patients with breast carcinomas.
Section snippets
Patient and tumour characteristics
All patients with operable breast cancer and treated between January 2000 and December 2001 at the Paul Strauss Center with neoadjuvant anthracycline-based chemotherapy were included in this retrospective study. Neo-adjuvant chemotherapy was indicated when the largest tumour diameter was equal to or larger than 20 mm. Patients with a primary inflammatory carcinoma or with a long clinical history of neglected tumour in breast were excluded. A microbiopsy was performed before the chemotherapy
Results
119 patients with operable breast cancer were treated with neoadjuvant anthracycline-based chemotherapy at the Paul Strauss Cancer Center between January 2000 and December 2001 (Table 1). All breast cancers were stage IC–IIIA invasive adenocarcinomas.
Discussion
In the present study, 119 patients with stage IC to IIIA invasive adenocarcinomas were treated with six cycles of an anthracycline-based therapy. The clinical OR was 80%, with 19% of CR. The radiological OR was 71%, with 16% of CR. No PD was observed during the chemotherapy. After surgery, a pathological CR was demonstrated in 9% of the patients according to the Chevallier classification and in 13% of the patients according to the Sataloff classification. With a higher kappa value, clinical
References (38)
- et al.
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response
Eur. J. Cancer
(2003) - et al.
HER2a predictive factor ready to use in the daily management of breast cancer patients?
Eur. J. Cancer
(2000) - et al.
Amplification and deletion of topoisomerase ha associate with HER-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
Am. J. Pathol.
(2000) - et al.
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
Ann. Oncol.
(2001) - et al.
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
Eur. J. Cancer
(2003) - et al.
Cell cycle modifications of breast cancers during neoadjuvant chemotherapya flow cytometry study on fine needle aspirates
Eur. J. Cancer
(1993) - et al.
Prediction of response to primary chemotherapy for operable breast cancer
Eur. J. Cancer
(1999) - et al.
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of HER-2 gene status in breast cancer
Mod. Pathol.
(2000) - et al.
Human DNA topoisomerase II alphaa new marker of cell proliferation in invasive breast cancer
Hum. Pathol.
(1997) - et al.
ErbB-2 overexpression in breast carcinomasno positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy
Eur. J. Cancer
(2000)
Topoisomerase IIα and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
Eur. J. Cancer
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
Br. J. Cancer
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer
J. Clin. Oncol.
DNA topoisomerase poisons as anti-tumor drugs
Ann. Rev. Biochem.
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate
Am. J. Clin. Oncol.
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breasta determinant of outcome
J. Am. Coll. Surg.
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
J. Immunol.
Pathological prognostic factors in breast cancer. The value of histological grade in breast cancerexperience from a large study with long-term follow-up
Histopathology
Statistical Methods for Rates and Proportions
Cited by (227)
Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer
2023, International Journal of Biological MacromoleculesEffective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer
2024, Iranian Journal of Pathology